{
  "meta": {
    "title": "Pharmacology_Rdx_Quiz",
    "url": "https://brainandscalpel.vercel.app/pharmacology-rdx-quiz-2800a932.html",
    "scrapedAt": "2025-11-30T08:53:30.825Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Patient can tolerate higher therapeutic concentration of lignocaine</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Lignocaine should be administered at sub-therapeutic doses</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to high risk of toxicity, lignocaine should be started at low doses and gradually increased</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Lignocaine must be administered at standard therapeutic doses</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old male diagnosed with acute myocardial ischemia develops ventricular arrhythmia. Lignocaine is planned to be administered for arrhythmia control. Which of the following statements is true about the therapeutic level of lignocaine in this patient?</span></p>",
      "unique_key": "Q322728",
      "question_audio": null,
      "question_video": null,
      "map_id": 322728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>In conditions like <strong>acute myocardial ischemia, inflammatory diseases, or trauma</strong>, plasma levels of <strong>&alpha;<sub>1</sub>-acid glycoprotein (AAG)</strong> increase as part of the <strong>acute phase response</strong>.</li><li>Lignocaine is a <strong>basic (cationic) drug</strong> that binds strongly to this protein.When AAG levels rise, a <strong>larger fraction of lignocaine binds</strong> to the protein, reducing the <strong>free (unbound) pharmacologically active concentration</strong> in plasma.</li><li>Because only <strong>free drug</strong> exerts therapeutic effects, patients with high AAG require a <strong>higher total plasma concentration</strong> of lignocaine to achieve the same <strong>effective free level</strong>.</li><li>Thus, these patients can <strong>tolerate higher therapeutic concentrations</strong> without increased risk of toxicity.</li></ul><p><strong>Explanation of the Incorrect Options:</strong></p><p><strong>Lignocaine should be administered at sub-therapeutic doses (Option B):</strong> Sub-therapeutic dosing will lead to <strong>ineffective arrhythmia control</strong>, as less free drug is available due to enhanced protein binding. In such patients, slightly higher doses are necessary, not lower.</p><p><strong>Due to high risk of toxicity, lignocaine should be started at low doses and gradually increased (Option C):</strong> Toxicity risk decreases in acute ischemic states because of increased drug binding to &alpha;<sub>1</sub>-acid glycoprotein. The free (toxic) fraction is reduced, so starting at low doses would delay reaching therapeutic efficacy.</p><p><strong>Lignocaine must be administered at standard therapeutic doses (Option D):</strong>The <strong>standard dose</strong> may not achieve the desired plasma effect in this patient because a higher percentage of lignocaine remains bound and inactive. Therefore, dose adjustment upward may be necessary.</p><p><strong>Key Takeaway:</strong>In conditions with <strong>elevated &alpha;<sub>1</sub>-acid glycoprotein (e.g., acute myocardial infarction, inflammatory disorders)</strong>, <strong>protein binding of basic drugs like lignocaine increases</strong>, reducing free drug concentration. Hence, <strong>higher total plasma concentrations</strong> are often needed to achieve therapeutic efficacy.</p>",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Patient can tolerate higher therapeutic concentration of lignocaine</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Flumazenil should be started at high doses to immediately reverse respiratory depression</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Fomepizole should be administered at high doses along with flumazenil</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Patient should be observed for respiratory depression and started on flumazenil at low doses</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 47-year-old patient with a 4-year history of chronic insomnia treated with alprazolam attempts suicide by ingesting more than 20 tablets of the drug. On arrival, the patient is drowsy but hemodynamically stable. Which of the following best describes the next appropriate step in management?</span></p>",
      "unique_key": "Q322729",
      "question_audio": null,
      "question_video": null,
      "map_id": 322729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>The patient has <strong>benzodiazepine overdose</strong> following <strong>chronic use</strong>, which implies <strong>tolerance and physical dependence</strong> to benzodiazepine's sedative effects.</li><li>The <strong>specific antidote</strong> for benzodiazepine toxicity is <strong>flumazenil</strong>, a <strong>competitive GABA-A receptor antagonist</strong> that rapidly reverses sedation and respiratory depression.</li><li>However, in <strong>chronic benzodiazepine users</strong>, administering <strong>high doses of flumazenil</strong> can <strong>precipitate acute withdrawal</strong>, leading to <strong>seizures, agitation, and arrhythmias</strong>.</li><li>Therefore, <strong>flumazenil should be initiated cautiously at low doses (&asymp;0.1 mg/kg IV)</strong> and titrated slowly every <strong>10-15 minutes</strong> while monitoring for respiratory depression.</li><li>Supportive care (airway, breathing, and circulation) remains the <strong>first-line management</strong> in all sedative overdoses.</li></ul><p><strong>Explanation of the Incorrect Options:</strong></p><p><strong>Patient should be observed for respiratory depression and administered naloxone multiple IV boluses (Option A): </strong>Naloxone is an <strong>opioid receptor antagonist</strong>, used for <strong>opioid overdose</strong> (e.g., morphine, heroin). It has <strong>no role</strong> in reversing benzodiazepine toxicity because benzodiazepines act on <strong>GABA-A receptors</strong>, not opioid receptors.</p><p><strong>Flumazenil should be started at high doses to immediately reverse respiratory depression (Option B): </strong>Administering high-dose flumazenil in a <strong>chronic benzodiazepine user</strong> is dangerous, as it can cause <strong>sudden withdrawal seizures</strong> and <strong>life-threatening CNS hyperexcitability</strong>. The dose must always be <strong>low and titrated slowly</strong>.</p><p><strong>Fomepizole is administered at high doses along with flumazenil (Option C): </strong>Fomepizole is the <strong>antidote for methanol or ethylene glycol poisoning</strong>, not benzodiazepine toxicity. It inhibits <strong>alcohol dehydrogenase</strong>, preventing toxic metabolite formation.</p><p><strong>Key Takeaway:</strong></p><p>In <strong>benzodiazepine overdose</strong>, especially in <strong>chronic users</strong>, treatment is mainly <strong>supportive</strong> with careful airway monitoring.<strong>Flumazenil</strong> is the <strong>specific antidote</strong>, but it should be <strong>started at low doses and titrated slowly</strong> to prevent <strong>withdrawal seizures</strong>.</p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Methanol intoxication</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Ethanol intoxication</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Methanol and Ethanol co-ingestion (Serum Ethanol < 100 mg/dL)</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Methanol and Ethanol co-ingestion (Serum Ethanol > 100 mg/dL)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In which of the following clinical situations should the initiation of Fomepizole be delayed?</span></p>",
      "unique_key": "Q322730",
      "question_audio": null,
      "question_video": null,
      "map_id": 322730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li><strong>Fomepizole</strong> is the <strong>drug of choice</strong> for treating <strong>methanol and ethylene glycol poisoning</strong>.</li><li>It acts as a <strong>competitive inhibitor of alcohol dehydrogenase (ADH)</strong>, preventing the conversion of methanol to <strong>formic acid</strong> and ethylene glycol to <strong>oxalic acid</strong>, which are responsible for metabolic acidosis and end-organ damage.</li><li>However, when <strong>ethanol is co-ingested</strong> and the <strong>serum ethanol level exceeds 100 mg/dL</strong>, ethanol itself <strong>competitively inhibits alcohol dehydrogenase</strong>, providing the same protective effect that fomepizole would.</li><li>In such cases, <strong>initiating fomepizole immediately is unnecessary and potentially unsafe</strong>, as it would <strong>further inhibit ethanol metabolism</strong>, increasing <strong>CNS depression</strong> due to elevated ethanol levels.</li><li>Hence, <strong>fomepizole administration is delayed</strong> until the <strong>serum ethanol concentration falls below 100 mg/dL</strong>, after which fomepizole therapy can safely begin.</li></ul><p><strong>Explanation of the Incorrect Options:</strong></p><p><strong>Methanol intoxication (Option A): </strong>In <strong>pure methanol poisoning</strong>, fomepizole must be <strong>started immediately</strong> to prevent formation of toxic metabolites (formic acid). Delay in initiation can lead to <strong>severe metabolic acidosis, optic neuritis, and blindness</strong>.</p><p><strong>Ethanol intoxication (Option B): </strong>Fomepizole is <strong>contraindicated</strong> in <strong>isolated ethanol intoxication</strong>, as it would inhibit ethanol metabolism, prolonging intoxication and worsening <strong>CNS and respiratory depression</strong>.</p><p><strong>Methanol and Ethanol co-ingestion (Serum Ethanol &lt; 100 mg/dL) (Option C): </strong>When serum ethanol levels are <strong>below 100 mg/dL</strong>, the protective competitive inhibition of ADH is lost; therefore, <strong>fomepizole should be started immediately</strong> to prevent methanol metabolism to toxic intermediates.</p><p><strong>Key Takeaway:</strong></p><p><strong>Fomepizole therapy is delayed only when serum ethanol levels exceed 100 mg/dL</strong>, as ethanol already inhibits alcohol dehydrogenase, preventing methanol metabolism. Once ethanol levels fall below this threshold, <strong>fomepizole should be initiated promptly</strong>.</p>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Isotretinoin decreases efficacy of doxycycline</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Doxycycline decreases efficacy of isotretinoin</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Both together have synergistic therapeutic responses</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Both together can cause adverse effects</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old woman with moderate acne vulgaris is started on a combination of doxycycline and isotretinoin. After a few days, she develops severe headache and visual blurring. Which of the following best explains why this drug combination is irrational?</span></p>",
      "unique_key": "Q322731",
      "question_audio": null,
      "question_video": null,
      "map_id": 322731,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>The combination of <strong>isotretinoin</strong> (a vitamin A derivative used for severe acne) and <strong>doxycycline</strong> (a tetracycline antibiotic) is <strong>contraindicated</strong> because <strong>both drugs independently increase intracranial pressure</strong>.</li><li>Their concurrent use greatly increases the risk of developing <strong>pseudotumor cerebri (benign intracranial hypertension)</strong>.</li><li>Typical features include <strong>headache, nausea, vomiting, papilledema, and visual disturbances</strong> due to increased cerebrospinal fluid pressure.</li><li>This adverse effect is thought to result from <strong>reduced cerebrospinal fluid absorption at the arachnoid villi</strong>.</li><li>If either drug is required, a <strong>washout period</strong> should be observed before switching from one to the other.</li></ul><p><strong>Explanation of the Incorrect Options:</strong></p><p><strong>Isotretinoin decreases efficacy of doxycycline (Option A):</strong> There is <strong>no pharmacokinetic or pharmacodynamic interaction</strong> reducing doxycycline's antibacterial efficacy. The issue is safety, not efficacy.</p><p><strong>Doxycycline decreases efficacy of isotretinoin (Option B):</strong> Doxycycline does not affect isotretinoin's action on sebaceous gland suppression or keratinization.</p><p><strong>Both together have synergistic therapeutic responses (Option C):</strong> Although both have roles in acne management, their combination offers <strong>no therapeutic advantage</strong> and instead <strong>increases toxicity risk</strong>.</p><p><strong>Key Takeaway:</strong></p><p><strong>Isotretinoin and doxycycline should never be used together</strong>, as both are associated with <strong>pseudotumor cerebri (benign intracranial hypertension)</strong>.Always evaluate for overlapping toxicity rather than combining for additive efficacy.</p>",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchospasm with wheezing</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Bradycardia with hypotension</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Skeletal muscle weakness</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Profuse sweating</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old farmer is brought to the emergency department with excessive salivation, sweating, abdominal cramps, and miosis after accidental exposure to an organophosphate pesticide. He is treated with atropine.<br>Which of the following manifestations of organophosphate poisoning would atropine not be able to prevent or reverse?</span></p>",
      "unique_key": "Q322732",
      "question_audio": null,
      "question_video": null,
      "map_id": 322732,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Atropine is a <strong>competitive antagonist at muscarinic receptors</strong>.</li><li>It effectively reverses muscarinic symptoms such as bronchospasm, bradycardia, sweating, and excessive secretions.</li><li>Skeletal muscle weakness is due to <strong>persistent depolarization of nicotinic receptors</strong> at the neuromuscular junction.</li><li>Atropine does not act on nicotinic receptors, so fasciculations and weakness persist and require <strong>pralidoxime (2-PAM)</strong>, which reactivates acetylcholinesterase.</li></ul><p><strong>Explanation of Incorrect Options:</strong></p><p><strong>Bronchospasm with wheezing (Option A):</strong> Incorrect, since mediated by muscarinic M3 receptors; atropine reverses this effect.</p><p><strong>Bradycardia with hypotension (Option B):</strong> Incorrect, as muscarinic M2 receptors in the heart mediate this effect; atropine blocks it effectively.</p><p><strong>Profuse sweating (Option D):</strong> Incorrect, because eccrine sweat glands are cholinergically innervated via M3 muscarinic receptors; atropine blocks this response.</p><p><strong>Key Takeaway:</strong> <strong>Atropine reverses muscarinic effects but not nicotinic receptor-mediated skeletal muscle weakness, which requires pralidoxime.</strong></p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">A</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">B</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">C</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An HIV-positive individual is noted to have multiple scrapable white lesions on oral examination. He is prescribed an antifungal drug. In the following diagram, which of the labelled steps is inhibited by this drug?<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/6Q.png\"></span></p>",
      "unique_key": "Q322733",
      "question_audio": null,
      "question_video": null,
      "map_id": 322733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation of the Answer:</strong></p><ul><li>The antifungal drug prescribed in this setting is an <strong>azole</strong> (commonly fluconazole for oropharyngeal candidiasis).</li><li>Azoles inhibit <strong>lanosterol 14-&alpha;-demethylase</strong>, a cytochrome P450-dependent enzyme that converts lanosterol into ergosterol.</li><li>By depleting ergosterol, they disrupt fungal cell membrane synthesis and function. In the diagram, this corresponds to <strong>step C</strong> in the ergosterol biosynthesis pathway.</li></ul><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/6E.png\"><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/6E1.png\"><p><strong>Key Takeaway:</strong><br />  Azoles act at step C by inhibiting lanosterol 14-&alpha;-demethylase, thereby blocking<strong> ergosterol synthesis</strong> and compromising fungal cell membrane integrity.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Lisinopril</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide (dose escalation)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old man with long-standing hypertension was initially treated with hydrochlorothiazide, but his blood pressure remained uncontrolled. His physician recently added another antihypertensive drug, and his blood pressure improved. Two weeks later, he presents with progressive swelling of both feet and ankles, which worsens toward the evening and leaves indentations when pressed. Cardiac and renal evaluations are normal.<br>Which of the following drugs would be most appropriate to add in order to relieve this swelling while maintaining blood pressure control?</span></p>",
      "unique_key": "Q322734",
      "question_audio": null,
      "question_video": null,
      "map_id": 322734,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation of the Answer:</strong></p><ul><li>The added agent in this patient is most likely <strong>amlodipine</strong>, a dihydropyridine calcium channel blocker.</li><li>Dihydropyridine CCBs cause <strong>selective arteriolar vasodilation</strong>. This leads to increased capillary hydrostatic pressure, promoting <strong>transudation of fluid into interstitial tissue</strong>, especially in gravity-dependent areas like ankles.</li><li>Importantly, this is <strong>not true fluid retention</strong>; total plasma volume remains normal.</li><li><strong>ACE inhibitors (eg, lisinopril)</strong> and <strong>ARBs</strong> cause <strong>post-capillary venodilation</strong>, which reduces capillary hydrostatic pressure, counterbalancing the arteriolar dilation and resolving edema without reducing the antihypertensive effect.</li><li>This combination (CCB + ACE inhibitor/ARB) is widely recommended because it reduces the risk of peripheral edema and provides additive blood pressure control.</li></ul><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/7E.png\"><p><strong>Explanation of Incorrect Options:</strong></p><p> <strong>Furosemide (Option A):</strong> Incorrect, because loop diuretics reduce plasma volume and are useful in edema due to <strong>heart failure, nephrotic syndrome, or CKD</strong>, but they do not correct the hemodynamic imbalance from arteriolar dilation.</p><p><strong>Spironolactone (Option C):</strong> Incorrect, as it targets <strong>aldosterone-mediated sodium retention</strong> (used in resistant hypertension, primary hyperaldosteronism, and heart failure with reduced EF). It does not improve vasodilatory edema.</p><p><strong>Hydrochlorothiazide dose escalation (Option D):</strong> Incorrect, because thiazides are already in use and additional dosing does not improve this CCB-induced ankle edema; instead, it increases risks such as <strong>hypokalemia, hyponatremia, and hyperuricemia</strong>.</p><p><strong>Key Takeaway:</strong></p><p> <strong>Edema from dihydropyridine CCBs is vasodilatory, not due to volume overload. It is best managed with an ACE inhibitor or ARB, not diuretics.</strong></p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Ototoxicity</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary edema</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyponatremia</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypercalcemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 59-year-old man presents with sudden-onset severe headache, nausea, and repeated vomiting. On examination, his blood pressure is 168/100 mmHg, pulse is 48/min, and respirations are 10/min and irregular. Fundoscopy shows bilateral papilledema. The patient is a known case of chronic heart failure. An intravenous agent is administered, and within the next few hours, the patient's urine output increases significantly. Which of the following adverse effects is this patient most at risk of developing with this therapy?</span></p>",
      "unique_key": "Q322735",
      "question_audio": null,
      "question_video": null,
      "map_id": 322735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation of the Answer:</strong></p><ul><li>This patient exhibits <strong>Cushing triad</strong> (hypertension, bradycardia, irregular respiration) and <strong>papilledema</strong>, consistent with <strong>raised intracranial pressure</strong>.</li><li>The IV drug used is <strong>mannitol</strong>, an osmotic diuretic that increases plasma osmolality, drawing water from the brain parenchyma into the circulation, thereby reducing cerebral edema.</li><li>Mannitol also promotes osmotic diuresis in the kidney, increasing urine output.</li><li>However, the <strong>intravascular volume expansion</strong> that occurs before diuresis predisposes to <strong>pulmonary edema</strong>, especially in patients with heart failure or compromised cardiac function.</li><li>High-yield: mannitol is contraindicated in <strong>congestive heart failure, pulmonary congestion, and anuria due to renal disease</strong>, because of this risk. </li></ul><p><strong>Explanation of Incorrect Options:</strong></p><p> <strong>Ototoxicity (Option A):</strong> Incorrect, this is a characteristic adverse effect of <strong>loop diuretics (e.g., furosemide, ethacrynic acid)</strong> due to effects on the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> transporter in the inner ear, not mannitol.</p><p><strong>Hyponatremia (Option C):</strong> Incorrect, typically caused by <strong>thiazide diuretics</strong>. Mannitol tends to cause <strong>hypernatremia</strong> as water is lost disproportionately compared to sodium.</p><p><strong>Hypercalcemia (Option D):</strong> Incorrect, since <strong>thiazides decrease calcium excretion</strong> and may cause mild hypercalcemia. Mannitol instead increases excretion of almost all electrolytes, including sodium and potassium, but does not raise calcium levels.</p><p><strong>Key Takeaway:</strong></p><p> <strong>Mannitol is used for cerebral edema but can precipitate pulmonary edema due to intravascular volume expansion.</strong></p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">3, 4, and 5</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 6</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, and 6</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 4, and 6</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman is diagnosed with major depressive disorder and started on fluoxetine. She is also prescribed additional medications for symptomatic relief. Below is a list of possible drugs:<br> 1.\tNaproxen<br> 2.\tParacetamol<br> 3.\tOndansetron<br> 4.\tTramadol<br> 5.\tLinezolid<br> 6.\tDomperidone<br> Which of the following combinations should be avoided in this patient due to the risk of serotonin syndrome?</span></p>",
      "unique_key": "Q322736",
      "question_audio": null,
      "question_video": null,
      "map_id": 322736,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li><strong>Fluoxetine</strong> is an SSRI that raises synaptic serotonin.</li><li><strong>Ondansetron (3):</strong> Although a 5-HT<sub>3</sub> antagonist, it can interfere with serotonergic signaling and is listed as a potential contributor to serotonin toxicity when combined with SSRIs.</li><li><strong>Tramadol (4):</strong> A weak &mu;-opioid agonist that also <strong>inhibits serotonin reuptake and increases serotonin release</strong> &rarr; high risk when combined with SSRIs.</li><li><strong>Linezolid (5):</strong> A reversible MAOI that blocks serotonin breakdown &rarr; the most dangerous in combination with SSRIs.</li><li>The combined serotonergic activity of these three agents can precipitate <strong>serotonin syndrome</strong>, characterized by <strong>neuromuscular hyperactivity (tremor, clonus), autonomic instability (hyperthermia, hypertension), and altered mental status (agitation, confusion)</strong>.</li></ul><p><strong>Key Takeaway:</strong></p><p>SSRIs combined with tramadol, linezolid, or ondansetron can trigger serotonin syndrome. Always avoid overlapping serotonergic drugs.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Both Assertion and Reason are correct, and Reason is the correct explanation of Assertion</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Both Assertion and Reason are correct, but Reason is not the correct explanation of Assertion</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is correct, but Reason is incorrect</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is incorrect, but Reason is correct</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Assertion (A): Capsaicin is useful in the treatment of post-herpetic neuralgia.<br>  Reason (R): Capsaicin binds to TRPV1 receptors, leading to depletion of substance P from sensory neurons, thereby reducing neuropathic pain.</span></p>",
      "unique_key": "Q322737",
      "question_audio": null,
      "question_video": null,
      "map_id": 322737,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li><strong>Post-herpetic neuralgia</strong> is a chronic neuropathic pain condition due to nerve injury from herpes zoster infection.</li><li><strong>Capsaicin</strong>, when applied topically, activates <strong>TRPV1 (transient receptor potential vanilloid-1) receptors</strong> on nociceptive C-fibers.</li><li>This initially causes depolarization and a burning sensation, but repeated exposure leads to <strong>defunctionalization of the neurons</strong> and <strong>depletion of substance P</strong>, a neuropeptide critical in transmitting pain signals.</li><li>As a result, nerve endings become desensitized, leading to long-term relief of neuropathic pain.</li><li>High-yield point: Capsaicin is FDA-approved for <strong>post-herpetic neuralgia</strong> and is also used in <strong>diabetic neuropathy</strong> and <strong>osteoarthritis</strong> topical pain relief. </li></ul><p><strong>Key Takeaway:</strong></p><p> <strong>Capsaicin relieves post-herpetic neuralgia by binding TRPV1 receptors, causing substance P depletion and sensory fibre desensitization.</strong></p>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Intracranial or intraspinal surgery performed in the past month</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Intracranial malignancy</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Previous exposure to streptokinase within the past 6 months</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypertension with systolic BP 190 mmHg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old man presents with acute chest pain for 90 minutes. ECG reveals ST-elevation in leads II, III, and aVF. The cardiology team is planning fibrinolytic therapy. Which of the following is not an absolute contraindication to fibrinolysis?</span></p>",
      "unique_key": "Q322738",
      "question_audio": null,
      "question_video": null,
      "map_id": 322738,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Severe hypertension at presentation (SBP &gt;180 mmHg or DBP &gt;110 mmHg) is a <strong>relative contraindication</strong> to fibrinolysis.</li><li>It can often be managed with rapid antihypertensive therapy before proceeding with thrombolysis.</li><li>Therefore, it is not an absolute contraindication.</li></ul><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/11E.png\"><p><strong>Explanation of Incorrect Options:</strong></p><p><strong>Intracranial or intraspinal surgery in the past month (Option A):</strong> Absolute contraindication due to very high risk of catastrophic intracranial bleeding.</p><p><strong>Intracranial malignancy (Option B):</strong> Absolute contraindication because of fragile vasculature and risk of fatal intracranial hemorrhage.</p><p><strong>Previous exposure to streptokinase within 6 months (Option C):</strong> Absolute contraindication, as anti-streptokinase antibodies can cause allergic reactions and neutralize efficacy.</p><p><strong>Key Takeaway:</strong> Absolute contraindications include intracranial hemorrhage, recent major neurosurgery/trauma, intracranial malignancy, and recent streptokinase exposure. <strong>Hypertension &gt;180/110 mmHg is only a relative contraindication.</strong></p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolonged PT only</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolonged PT and prolonged aPTT</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased platelet count</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal PT and aPTT</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old man with an acute ST-elevation myocardial infarction receives intravenous alteplase. Which of the following best describes the expected laboratory changes with this therapy?</span></p>",
      "unique_key": "Q322739",
      "question_audio": null,
      "question_video": null,
      "map_id": 322739,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Alteplase converts plasminogen to plasmin, causing degradation of fibrin and fibrinogen.</li><li>This consumptive process decreases fibrinogen and factors V and VIII, producing a systemic lytic state.</li><li>As a result, both PT (extrinsic pathway) and aPTT (intrinsic pathway) are prolonged.</li><li>Platelet count is not reduced, though fibrin degradation products may impair platelet function.</li><li>Alteplase is a recombinant tPA that binds fibrin in thrombi and initiates fibrinolysis.</li><li>Its action increases fibrin degradation products such as <strong>D-dimer</strong>, a commonly tested laboratory marker.</li><li>By lowering fibrinogen levels, it prolongs both PT and aPTT simultaneously, not one selectively.</li><li>Major adverse effect is <strong>bleeding</strong>, especially intracranial hemorrhage.</li><li>Contraindications include prior intracranial hemorrhage, recent major surgery, and severe uncontrolled hypertension.</li><li>Unlike streptokinase, alteplase is non-antigenic, making it safe for repeat use.</li></ul><p><strong>Explanation of Incorrect Options:</strong><strong>Prolonged PT only (option A):</strong> Incorrect, alteplase does not selectively affect the extrinsic pathway; both PT and aPTT are prolonged.</p><p><strong>Decreased platelet count (option C):</strong> Incorrect, alteplase does not cause thrombocytopenia (unlike heparin-induced thrombocytopenia), though fibrin degradation products may secondarily impair platelet function.</p><p><strong>Normal PT and aPTT (option D):</strong> Incorrect, fibrinolysis invariably prolongs both PT and aPTT due to consumption of clotting factors.</p><p><strong>Key Takeaway:</strong></p><p> Fibrinolytic therapy with alteplase prolongs both PT and aPTT by consuming fibrinogen and clotting factors, without causing true thrombocytopenia.</p>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">1-b, 2-e, 3-a, 4-c, 5-d</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-b, 3-e, 4-d, 5-c</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">1-c, 2-a, 3-d, 4-e, 5-b</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">1-d, 2-c, 3-b, 4-a, 5-e</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following asthma drugs with their primary mechanisms of action:<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/13Q.png\"></span></p>",
      "unique_key": "Q322740",
      "question_audio": null,
      "question_video": null,
      "map_id": 322740,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Salbutamol &rarr; b. Stimulates adenylyl cyclase &rarr; &uarr; cAMP<> Salbutamol is a <strong>short-acting &beta;2 agonist (SABA)</strong>. By stimulating &beta;2 receptors, it activates adenylyl cyclase, leading to <strong>increased cAMP</strong> and <strong>bronchodilation</strong>. It is the <strong>first-line drug for acute asthma attacks</strong> due to its rapid onset. Side effects include <strong>tremor, palpitations, and hypokalemia</strong>.</li><li>Theophylline &rarr; e. Inhibits phosphodiesterase &rarr; &uarr; cAMP<> Theophylline is a <strong>methylxanthine</strong> that inhibits <strong>phosphodiesterase (PDE)</strong>, preventing cAMP breakdown and maintaining bronchodilation. It also <strong>improves diaphragmatic contractility</strong>. It has a <strong>narrow therapeutic index</strong>, with toxicity causing <strong>arrhythmias and seizures</strong>.</li><li>Montelukast &rarr; a. Blocks leukotriene D4 receptors<> Montelukast is a <strong>leukotriene receptor antagonist (LTRA)</strong>. By blocking leukotriene D4 receptors, it reduces <strong>airway edema, inflammation, and bronchoconstriction</strong>. It is especially useful for <strong>aspirin-induced asthma</strong> and <strong>exercise-induced bronchospasm</strong>. High-yield adverse effect: <strong>neuropsychiatric symptoms</strong> (eg, depression, agitation).</li><li>Omalizumab &rarr; c. Prevents IgE binding to mast cells and basophils<> Omalizumab is an <strong>anti-IgE monoclonal antibody</strong>. It prevents free IgE from binding mast cells and basophils, thus <strong>reducing allergen-triggered degranulation</strong>. It is used in <strong>severe, refractory allergic asthma</strong> not controlled by corticosteroids and &beta;2 agonists.</li><li>Cromolyn sodium &rarr; d. Prevents mast cell degranulation<> Cromolyn sodium is a <strong>mast cell stabilizer</strong> that prevents degranulation and release of <strong>histamine and inflammatory mediators</strong>. It is used <strong>prophylactically</strong>, not for acute attacks. Though less common today, it is a <strong>classic exam favorite</strong> for its unique role.</li></ul><p><strong>Key Takeaway:</strong></p><p>Asthma drugs act via different mechanisms: &beta;2 agonists (salbutamol) cause bronchodilation via cAMP, theophylline inhibits PDE, montelukast blocks leukotrienes, omalizumab targets IgE, and cromolyn prevents mast cell degranulation.</p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-C, 3-B, 4-D</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D, 2-B, 3-A, 4-C</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-A, 3-D, 4-C</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-D, 3-B, 4-A</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs with their corresponding clinical uses or mechanisms of action.<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/14Q.png\"></span></p>",
      "unique_key": "Q322741",
      "question_audio": null,
      "question_video": null,
      "map_id": 322741,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation of the Answer:</strong></p><ul><li><strong>Neostigmine - Treatment of paralytic ileus (1-B):</strong>Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine at neuromuscular junctions and muscarinic sites. In paralytic ileus and postoperative urinary retention, it enhances GI motility by stimulating muscarinic receptors in the gut. Clinically, it is also used in <strong>myasthenia gravis</strong> (first-line symptomatic drug), and to <strong>reverse non-depolarizing neuromuscular blockade</strong> (e.g., vecuronium). Important to note: it causes bradycardia, so <strong>atropine is often co-administered</strong>.</li><li><strong>Bethanechol - non-obstructive urinary retention (2-A):</strong><> Bethanechol is a direct muscarinic agonist, selective for M3 receptors on detrusor muscle. It stimulates bladder contraction and increases ureteral peristalsis, relieving postoperative or postpartum urinary retention. Unlike neostigmine, it does not inhibit acetylcholinesterase, so it has <strong>no nicotinic effects</strong>. Side effects include <strong>diarrhea, bronchospasm, sweating, and hypotension</strong>. Contraindicated in <strong>mechanical obstruction of the urinary tract</strong>.</li><li><strong>Tiotropium - COPD (3-D):</strong><> Tiotropium is a long-acting muscarinic antagonist (LAMA), binding M3 receptors in bronchial smooth muscle. It reduces bronchoconstriction and mucus secretion, providing once-daily bronchodilation. It is a mainstay in <strong>COPD management</strong> and sometimes used in severe asthma. A high-yield point: unlike ipratropium (short-acting), tiotropium dissociates slowly, giving prolonged effect. Side effects include <strong>dry mouth, urinary retention, and glaucoma precipitation</strong> if nebulized.</li><li><strong>Phenylephrine - Mydriasis without cycloplegia (4-C):</strong><> Phenylephrine is a selective &alpha;1-adrenergic agonist. In ophthalmology, it dilates the pupil by contracting the radial muscle of the iris, but because it does not affect muscarinic control of the ciliary muscle, it spares accommodation (no cycloplegia). It is also used as a <strong>nasal decongestant</strong> and as a <strong>vasopressor in hypotension</strong>. A high-yield exam fact: unlike tropicamide (M3 antagonist), phenylephrine does not cause blurred near vision.</li></ul><p><strong>Key Takeaway:</strong></p><ul><li>Neostigmine &rarr; paralytic ileus, myasthenia gravis, reversal of neuromuscular blockade</li><li>Bethanechol &rarr; urinary retention, selective muscarinic agonist</li><li>Tiotropium &rarr; COPD, long-acting muscarinic antagonist</li><li>Phenylephrine &rarr; mydriasis without cycloplegia, nasal decongestant, vasopressor</li></ul>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Curve A</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Curve B</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Curve C</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Curve D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 20-year-old man presents with abdominal pain, nausea, vomiting, polyuria, and polydipsia. Examination reveals tachypnea and dehydration. Laboratory studies show hyperglycemia and urine positive for ketones. He is started on intravenous fluids and insulin therapy. The subcutaneous form of the insulin used in this patient best corresponds to which of the following curves on the graph?<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/15Q.png\"></span></p>",
      "unique_key": "Q322742",
      "question_audio": null,
      "question_video": null,
      "map_id": 322742,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>This patient has <strong>diabetic ketoacidosis (DKA)</strong>, which is treated with <strong>intravenous regular insulin</strong>.</li><li>Intravenous <strong>regular insulin</strong> has a rapid onset of action, begins lowering glucose and ketone levels within minutes, and has a half-life of about 5 minutes, making it ideal for acute DKA management.</li><li>When given <strong>subcutaneously</strong>, regular insulin demonstrates an <strong>onset of 30 minutes, peak at 2-4 hours, and duration of 5-8 hours</strong>, corresponding to <strong>Curve B</strong> on the graph. The delayed absorption is due to <strong>hexamer formation in subcutaneous tissue</strong>, which slows entry into the circulation.</li><li>Subcutaneous regular insulin is commonly used as a <strong>prandial insulin</strong> and is paired with basal insulin (eg, NPH, glargine) for long-term glycemic control. Regular insulin and NPH are the only <strong>human recombinant insulins without amino acid modifications</strong>; other insulin types (eg, lispro, aspart, glargine) are considered analogs.</li></ul><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/15E.png\"><ul><li><strong>Curve A (Option A ruled out):</strong> Rapid-acting insulin analogs (aspart, lispro, glulisine). Onset ~15 minutes, peak at 45-75 minutes. Mimic physiologic postprandial insulin release more closely than regular insulin.</li><li><strong>Curve C (Option C ruled out):</strong> Intermediate-acting insulin (NPH). Onset ~2 hours, peak 4-6 hours, duration up to 16 hours. Used as basal insulin, not for IV use.</li><li><strong>Curve D (Option D ruled out):</strong> Long-acting insulin analog (detemir). Flat profile, duration close to 24 hours, less suitable for postprandial control.</li><li><strong>Curve E:</strong> Represents ultra-long-acting insulin (glargine, degludec) with minimal peak and &gt;24-hour duration.</li></ul><p><strong>Key Takeaway:</strong></p><p>Regular insulin is used intravenously in DKA for rapid correction and subcutaneously for postprandial control. Subcutaneous administration has delayed onset and longer duration due to polymerization, corresponding to <strong>Curve B</strong>.</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Linagliptin</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Amlodipine</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Atorvastatin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old man with type 2 diabetes mellitus presents with several weeks of pruritic skin lesions. Physical examination of lesions is given below. A biopsy confirms subepidermal blistering with linear IgG and C3 deposition along the basement membrane. The patient's medications include metformin, linagliptin, and amlodipine and Atorvastatin. Which of the following drugs is the most likely cause of this patient' condition?<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/16Q.png\"></span></p>",
      "unique_key": "Q322743",
      "question_audio": null,
      "question_video": null,
      "map_id": 322743,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Bullous pemphigoid is an <strong>autoimmune blistering disorder</strong> caused by autoantibodies against hemidesmosomal proteins in the dermoepidermal junction.</li><li>It presents with <strong>tense, pruritic bullae</strong> and is confirmed by immunofluorescence showing linear IgG and C3 along the basement membrane.</li><li>Certain drugs can trigger or exacerbate bullous pemphigoid. Among antidiabetic agents, <strong>dipeptidyl peptidase-4 (DPP-4) inhibitors</strong> such as <strong>linagliptin,</strong> have been associated with an increased risk.</li></ul><p><strong>Explanation of Incorrect Options</strong></p><p><strong>Metformin (Option A):</strong> Most common adverse effects are gastrointestinal intolerance and lactic acidosis in renal dysfunction; not linked to bullous pemphigoid.</p><p><strong>Amlodipine (Option C):</strong> Can cause peripheral edema, flushing, and headache; not associated with blistering disorders.</p><p><strong>Atorvastatin (Option D):</strong> A statin used for dyslipidemia. Adverse effects include hepatotoxicity and myopathy (rarely  arhabdomyolysis). It is not linked to bullous pemphigoid.</p><p><strong>Key Takeaway:</strong></p><p>Bullous pemphigoid can be drug-induced,nd <strong>DPP-4 inhibitors (gliptins such as linagliptin)</strong> are a recognized cause.</p>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatitis</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Myopathy</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Neutropenia</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephrotoxicity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old renal transplant recipient on immunosuppressive therapy develops fever, abdominal pain, and diarrhea. Colonoscopy reveals mucosal ulcerations, and biopsy shows large cells with intranuclear inclusions. A viral PCR confirms CMV infection, and first-line therapy is initiated. This patient is at greatest risk of developing which of the following adverse effects from the treatment?</span></p>",
      "unique_key": "Q322744",
      "question_audio": null,
      "question_video": null,
      "map_id": 322744,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation</strong></p><p>First-line therapy for <strong>CMV colitis</strong> is <strong>ganciclovir</strong>, a guanine nucleoside analogue that competitively inhibits CMV DNA polymerase. It has poor oral bioavailability, so <strong>valganciclovir</strong> (a prodrug) is used orally; ganciclovir can also be delivered by intraocular implants in CMV retinitis.</p><p>The most important adverse effect of ganciclovir is <strong>bone marrow suppression</strong> (dose-limiting toxicity), presenting as <strong>neutropenia, thrombocytopenia, and anemia</strong>. Other side effects include fever and seizures (particularly if combined with imipenem).</p><p><strong>Explanation of Incorrect Options</strong></p><p><strong>Hepatitis (Option A):</strong> A complication of antitubercular drugs such as isoniazid or pyrazinamide, not ganciclovir.</p><p><strong>Myopathy (Option B):</strong> Seen with HIV integrase inhibitors such as raltegravir, not ganciclovir.</p><p><strong>Nephrotoxicity (Option D):</strong> Characteristic of <strong>foscarnet</strong>, the second-line agent for CMV or acyclovir-resistant herpes. Foscarnet acts directly on DNA polymerase without requiring phosphorylation. It causes <strong>hypocalcemia, hypomagnesemia, and direct tubular nephrotoxicity</strong>. It is reserved for patients intolerant to or resistant to ganciclovir.</p><p><strong>Key Takeaway:</strong></p><p>Ganciclovir is the first-line drug for CMV infections, with bone marrow suppression (especially neutropenia) as the major adverse effect. Foscarnet is used when ganciclovir is contraindicated and is associated with nephrotoxicity and electrolyte disturbances</p>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-b, 3-c, 4-d</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">1-c, 2-d, 3-a, 4-b</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">1-d, 2-a, 3-b, 4-c</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">1-b, 2-c, 3-d, 4-a</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs (Column 1) with the congenital anomaly most classically associated with them (Column 2)<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/18Q.png\">.</span></p>",
      "unique_key": "Q322745",
      "question_audio": null,
      "question_video": null,
      "map_id": 322745,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li><strong>Methimazole &rarr; Aplasia cutis</strong><ul><li>Methimazole is an <strong>antithyroid drug</strong>. When taken during pregnancy, it can cause <strong>aplasia cutis congenita</strong> - absence of a portion of skin, usually on the <strong>scalp</strong>. It presents as <strong>well-demarcated skin defects</strong> with possible ulceration or scarring.<img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/18E.png\"></li></ul></li><li><strong>Thalidomide &rarr; Phocomelia</strong><ul><li>Thalidomide, once used as a sedative and antiemetic in pregnancy, interferes with <strong>limb development</strong>. The classic defect is <strong>phocomelia (\"flipper limbs\")</strong> where <strong>long bones are absent or underdeveloped</strong>, and hands/feet attach close to the trunk.<img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/18E1.png\"></li></ul></li><li><strong>Warfarin &rarr; Stippled epiphysis </strong><ul><li>Warfarin is a <strong>vitamin K antagonist</strong> that <strong>crosses the placenta</strong>. Fetal exposure disrupts cartilage and bone development. The hallmark finding is <strong>stippled epiphyses on X-ray (punctate calcifications)</strong>. Other features include <strong>nasal hypoplasia and skeletal anomalies</strong> - the constellation is sometimes called <strong>fetal warfarin syndrome</strong>.<img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/18E2.png\"></li></ul></li><li><strong>Valproate &rarr; Neural tube defects </strong><ul><li>Valproate interferes with <strong>folate metabolism</strong>, increasing the risk of <strong>neural tube closure defects</strong>. The most common is <strong>spina bifida</strong>, which may appear clinically as a <strong>tuft of hair, sac, or skin dimple over the spine</strong>.<img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/18E3.png\"></li></ul>",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, and R is the correct explanation of A</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, but R is not the correct explanation of A</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">A is true, but R is false</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">A is false, but R is true</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Assertion-Reason Question <br>Assertion (A): Clozapine is associated with the lowest risk of extrapyramidal side effects among antipsychotics. Reason <br>(R): This is because clozapine exhibits predominant D2 receptor blockade compared to 5-HT2A receptor blockade.</span></p>",
      "unique_key": "Q322746",
      "question_audio": null,
      "question_video": null,
      "map_id": 322746,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>Clozapine indeed has the <strong>lowest risk of extrapyramidal side effects (EPS)</strong> because it has the <strong>least D2 receptor blockade</strong> among antipsychotics (only enough for efficacy, blockade level ~3).</li><li>Instead, its main action is <strong>strong 5-HT2A receptor antagonism</strong>, which reduces dopamine blockade in the nigrostriatal pathway, sparing patients from EPS.</li><li>Therefore, while the assertion is true, the reason is false because the statement mixes up the receptor selectivity - clozapine is defined by <strong>higher 5-HT2A blockade than D2 blockade</strong>, not the reverse.</li></ul><p><strong>clozapine:</strong></p><ul><li><strong>Agranulocytosis</strong>: Dose-independent, requires mandatory blood count monitoring and discontinuation if it occurs.</li><li><strong>Other serious adverse effects (mnemonic \"Agra is close to Delhi, and Pondy is close to Madras\"):</strong><br /> Agra &rarr; Agranulocytosis<br />&bull; Delhi &rarr; Dry mouth &amp; Diabetes<br /> &bull; Pondy &rarr; Postural hypotension &amp; Pulmonary embolism<br /> &bull; Madras &rarr; Myocarditis</li><li><strong>Other adverse effects:</strong> Sedation, seizures (dose-dependent), sialorrhea (M4 blockade), weight gain, QT prolongation.</li><li><strong>Drug interactions:</strong> Smoking induces CYP450 metabolism, requiring higher doses in smokers. After smoking cessation, clozapine dose must be reduced by 30-50%.</li></ul><p><strong>Key Takeaway</strong></p><p><strong>Clozapine has the least EPS risk because it has minimal D2 blockade and stronger 5-HT2A antagonism.</strong> Typical antipsychotics (eg, haloperidol) with strong D2 blockade have the <strong>highest risk of EPS</strong>.</p>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Step A</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Step B</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Step C</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Step D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old woman with a history of untreated Graves' disease presents with high fever, agitation, severe tachycardia, and profuse sweating following an upper respiratory tract infection. On examination, she is restless, anxious, and has a heart rate of 150/min. The next immediate drug is administered to stabilize the patient.<br><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/20Q.png\"><br>According to the diagram provided, this drug primarily inhibits which of the following steps?</span></p>",
      "unique_key": "Q322747",
      "question_audio": null,
      "question_video": null,
      "map_id": 322747,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong>Explanation:</strong></p><ul><li>The patient has developed <strong>thyroid storm</strong>, a life-threatening complication of untreated hyperthyroidism precipitated by surgery or infection.</li><li>The most immediate drug given is a <strong>beta blocker (eg, propranolol)</strong>, which not only controls adrenergic manifestations but also <strong>inhibits peripheral conversion of T4 to T3</strong>.</li><li>This corresponds to <strong>Step D</strong> in the diagram.</li></ul><img class=\"w-100\" style=\"width:50%;height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/Quiz2025/NEETPG/QuizOct2025/PhramacologyRDx12102025/20E.png\"><p><strong>Explanation of Incorrect Options</strong></p><p><strong>Step A (Iodide transport):</strong> This step represents uptake of iodide into the thyroid follicular cell. It can be blocked by <strong>thiocyanate</strong> or <strong>perchlorate</strong>, but these are not used in thyroid storm.</p><p><strong>Step B (Oxidation &amp; organification):</strong> This is catalyzed by <strong>thyroid peroxidase</strong> and inhibited by <strong>thionamides (methimazole, PTU)</strong>. PTU is sometimes used in thyroid storm, but the very first drug given is a beta blocker.</p><p><strong>Step C (Proteolysis of thyroglobulin):</strong> This step releases preformed T3 and T4 into circulation. It can be inhibited by <strong>high-dose iodide (eg, Lugol's solution)</strong>, which is used only after thionamide administration to avoid increased hormone synthesis.</p><p><strong>Educational Objective</strong></p><p>In thyroid storm, the most immediate pharmacologic therapy is <strong>beta blockers</strong>, which rapidly control symptoms and inhibit <strong>peripheral T4 to T3 conversion</strong> (Step D). Other drugs- <strong>thionamides (Step B)</strong>, <strong>iodide (Step C)</strong>, and <strong>glucocorticoids (Step D)- </strong>are also used sequentially but are not the first immediate step.</p>",
      "correct_choice_id": 194,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}